Sanuwave Health, Inc. income statement
In fiscal 2025, Sanuwave Health, Inc. reported revenue of $44.1m, up 35.0% on the year before, operating income of $4.9m (a 11.2% margin) and net income of $11.8m, or $0.41 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 13 | 17 | 20 | 33 | 44 | 44 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 5 | 4 | 6 | 8 | 10 | 10 |
| Gross profit | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 3 | 8 | 12 | 14 | 25 | 34 | 34 |
| Research and development | 4 | 3 | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Selling and marketing | — | — | — | — | — | — | — | — | 1 | 2 | 5 | 9 | 7 | 5 | 6 | 7 | 9 |
| General and administrative | 7 | 6 | 5 | 4 | 3 | 3 | 3 | 3 | 7 | 6 | 14 | 12 | 13 | 9 | 13 | 19 | 20 |
| Operating income | −12 | −9 | −6 | −6 | −6 | −4 | −3 | −4 | −7 | −9 | −25 | −14 | −9 | −1 | 4 | 5 | 2 |
| Interest expense | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 2 | 2 | 7 | 13 | — | 13 | — | — |
| Income before tax | −15 | −10 | −6 | −12 | −6 | — | — | — | — | — | — | — | — | — | −33 | 12 | — |
| Income tax | −0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Net income | −15 | −10 | −6 | −11 | −6 | −5 | −6 | −6 | −12 | −10 | −31 | −27 | −10 | −26 | −33 | 12 | 15 |
| Diluted EPS | −$0.29 | −$0.13 | −$0.07 | −$0.10 | −$0.03 | −$0.02 | −$0.01 | −$0.01 | −$0.02 | −$0.01 | −$0.02 | −$0.01 | −$0.01 | −$3.05 | −$3.71 | $0.41 | $1.70 |
| Diluted shares (average) | 52m | 78m | 84m | 113m | 193m | 252m | 430m | 555m | 598m | 814m | 1,513m | 2,073m | 2,198m | 8m | 9m | 9m | 9m |
| EBITDA | −11 | −9 | −6 | −6 | −6 | −4 | −3 | −4 | −7 | −9 | −25 | −13 | −8 | 0 | 5 | 6 | 3 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 10 | 9 | 10 | 11 | 13 | 10 | 10 |
| Cost of revenue | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 2 |
| Gross profit | 7 | 8 | 7 | 8 | 9 | 10 | 7 | 7 |
| Research and development | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Selling and marketing | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| General and administrative | 3 | 4 | 5 | 4 | 5 | 5 | 5 | 5 |
| Operating income | 1 | 2 | 1 | 1 | 1 | 2 | −1 | −0 |
| Interest expense | 3 | 3 | 2 | 2 | 2 | — | 1 | 1 |
| Income tax | — | — | — | 0 | — | — | — | 0 |
| Net income | −21 | −13 | −6 | 1 | 10 | 8 | −1 | −1 |
| Diluted EPS | −$6.65 | −$1.12 | −$0.72 | −$0.04 | $0.39 | $0.20 | −$0.17 | −$0.08 |
| EBITDA | 2 | 2 | 1 | 2 | 1 | 2 | −1 | −0 |
Compare with peers
- Myomo, Inc. income statement
- Trisalus Life Sciences, Inc. income statement
- Koru Medical Systems, Inc. income statement
- Clearpoint Neuro, Inc. income statement
- Senseonics Holdings, Inc. income statement
Head to head: MYO vs SNWVSNWV vs TLSIKRMD vs SNWVCLPT vs SNWV
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies